Robert E Goldsby
Affiliation: University of California
- Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology GroupRobert E Goldsby
University of California San Francisco, Benioff Children s Hospital, San Francisco, CA, United States Electronic address
Eur J Cancer 49:2384-91. 2013..This study assessed the maximum tolerated dose (MTD) and the feasibility of ZA when combined with chemotherapy in patients with metastatic OS...
- Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor StudyRobert E Goldsby
UCSF Pediatric Oncology, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143 0106, USA
J Clin Oncol 28:324-31. 2010..Little is known about the incidence and severity of late-occurring neurologic sequelae in ALL survivors. Data were analyzed to determine the incidence of adverse long-term neurologic outcomes and treatment-related risk factors...
- Survivors of childhood cancer have increased risk of gastrointestinal complications later in lifeRobert Goldsby
Pediatric Hematology Oncology, UCSF Benioff Children s Hospital, San Francisco, California, USA
Gastroenterology 140:1464-71.e1. 2011..However, the long-term GI consequences have not been extensively studied. We evaluated the incidence of long-term GI outcomes and identified treatment-related risk factors...
- Surviving childhood cancer: the impact on lifeRobert E Goldsby
Division of Pediatric Hematology Oncology, University of California, San Francisco, USA
Paediatr Drugs 8:71-84. 2006..Guidelines for long-term follow-up have been established and are available to help facilitate appropriate monitoring of and care for potential late effects...
- Surviving childhood cancer; now what? Controversies regarding long-term follow-upRobert E Goldsby
Pediatric Oncology, UCSF Box 0106, San Francisco, CA 94143 0106, USA
Pediatr Blood Cancer 43:211-4. 2004
- Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor StudySabine Mueller
Department of Neurology, Pediatrics and Neurosurgery, University of California, San Francisco, San Francisco, California 94158, USA
Int J Radiat Oncol Biol Phys 86:649-55. 2013..To test the hypotheses that (1) the increased risk of stroke conferred by childhood cranial radiation therapy (CRT) persists into adulthood; and (2) atherosclerotic risk factors further increase the stroke risk in cancer survivors...
- Survival after recurrence of osteosarcoma: a 20-year experience at a single institutionBrian D Crompton
Department of Pediatrics, UCSF Children s Hospital, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 47:255-9. 2006..We present findings in 59 patients treated at our institution from 1974 to 1996 who have relapsed one or more times after their initial response...
- Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosisErin E Karski
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA 94143 0106, USA
Cancer Epidemiol 37:29-33. 2013..The peak incidence of Ewing sarcoma (EWS) is in adolescence, with little known about patients who are ≥40 years at diagnosis. We describe the clinical characteristics and survival of this rare group...
- Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)Paul A Fitzgerald
Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
Ann N Y Acad Sci 1073:465-90. 2006..For patients with metastatic PHEO or PGL, who have good *I-MIBG uptake on diagnostic scanning, high-dose 131I-MIBG therapy was effective in producing a sustained CR, PR, or SD in 67% of patients, with tolerable toxicity...
- Patellar metastatic melanoma in a 13-year-old boyThomas F Burk
Department of Orthopaedic Surgery, University of California, San Francisco, USA
Am J Orthop (Belle Mead NJ) 39:582-6. 2010....
- Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumorsLars M Wagner
Division of Pediatric Hematology Oncology, University of Utah Primary Children s Medical Center, Salt Lake City, Utah, USA
Clin Cancer Res 10:840-8. 2004..The purpose is to estimate the maximum-tolerated dose (MTD) of temozolomide and irinotecan given on a protracted schedule in 28-day courses to pediatric patients with refractory solid tumors...
- Seeding of osteosarcoma in the biopsy tract of a patient with multifocal osteosarcomaKriengkrai Iemsawatdikul
Department of Radiology, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 0628, USA
Pediatr Radiol 35:717-21. 2005..We report a case of multifocal osteosarcoma in a 7-year-old boy who developed iatrogenic seeding of tumor along the biopsy tract. The results of the plain radiograph, CT, and histopathological correlation are presented...
- Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablationWarapat Virayavanich
Department of Radiology, University of California San Francisco, San Francisco, CA, USA
Skeletal Radiol 39:1145-9. 2010..In summary, this case report shows that osteoid osteoma can present in early infancy and can be successfully treated with RFA at this age, however, recurrence after the procedure can occur and close follow-up is recommended...
- Ewing sarcoma as a second malignant neoplasm after acute lymphoblastic leukemiaGrace E Kim
UCSF Children s Hospital, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 45:57-9. 2005..Second malignant neoplasms are relatively rare in survivors of ALL treated without radiation. Even more unusual is the development of Ewing sarcoma as the SMN...
- Receptor imaging of pediatric tumors: clinical practice and new developmentsHeike E Daldrup-Link
Department of Radiology, University of California at San Francisco, San Francisco, CA 94131, USA
Pediatr Radiol 38:1154-61. 2008....
- Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesisRanga N Venkatesan
Department of Pathology, University of Washington, Seattle, WA 98195 7705, USA
Mol Cell Biol 27:7669-82. 2007....